SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that CEO Dwight Egan will represent Co-Diagnostics as a Presenting Company at the 24th Annual Biocentury NewsMakers in the Biotech Industry conference, held on September 8 in New York City.
According to their website, NewsMakers presents a hand-picked group of public biotech companies whose corporate and regulatory milestones are expected to drive stock prices, and describes itself as the best opportunity for business development executives and key members of the institutional investment and analyst communities to compare notes and assess the industry landscape. The 2016 conference represented more than 500 delegates, including money managers with more than $600 billion in equity assets. Co-Diagnostics will be participating as a Presenting Company and will additionally host a table at the working luncheon. The Company’s presentation will be available via webcast, which can be reached here: http://www.wsw.com/webcast/biocentury4/codg.
Mr. Egan commented: “NewsMakers is recognized as a key venue in the industry for companies to present their story to the investment community on Wall Street. As a NASDAQ-listed company, we look forward to the opportunity to share our high-margin value proposition as a dynamic company with groundbreaking technology, and our strategy for success.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Disclaimer:
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170907005619/en/
Co-Diagnostics
Andrew Benson, Investor Relations
801-438-1036
investors@codiagnostics.com